Insight

Pietro De Placido: The SURVIVE Study will challenge the “no symptoms, no scan” BC surveillance model

Pietro De Placido/LinkedIn

Feb 26, 2025, 10:54

Pietro De Placido: The SURVIVE Study will challenge the “no symptoms, no scan” BC surveillance model

Pietro De Placido, Medical Oncologist at Dana-Farber Cancer Institute, a post on X about a paper by Kerstin Pfister et al. published in Journal of Clinical Oncology:

“The SURVIVE Study (NCT05658172) will challenge the ‘no symptoms, no scan’ BC surveillance model.

3,500 high-risk EBC patients will be randomized to standard vs. liquid biopsy-guided follow-up.

Costly if effective? Prevention beats cure.”

“The SURVIVE study: Liquid biopsy guided surveillance after intermediate- to high-risk early breast cancer”

Authors: Kerstin Pfister, Sophia Huesmann, Thomas Friedl, Brigitte Rack, Wolfgang Janni et al.

Pietro De Placido: The SURVIVE Study will challenge the "no symptoms, no scan" BC surveillance model

More posts featuring Pietro De Placido.

Breast Cancer Brigitte Rack cancer Kerstin Pfister liquid biopsy OncoDaily Oncology Pietro De Placido Sophia Huesmann SURVIVE study Thomas Friedl Wolfgang Janni

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term